Clarient, Inc. (CLRT) - Product Pipeline Analysis by GlobalData

VIEWS: 20 PAGES: 29

More Info
									                                             Clarient, Inc. (CLRT) - Product Pipeline Analysis

     Reference Code: GDMEPH4068PD                                                                                                 Publication Date: NOV 2010



     Company Snapshot                                                           Company Overview
     Key Information
                                                                                Clarient, Inc. (Clarient) is an oncology diagnostics services company
      Clarient, Inc., Key Facts                                                 engaged in providing cellular assessment and cancer characterization.
                                                                                The company also focuses on providing advanced oncology testing and
      Web Address                             www.clarientinc.com
                                                                                diagnostic services to oncologists, pathologists, hospitals and bio-
      Turnover (in USD Million)               91.60                             pharmaceutical companies and other researchers. It provides a range of
                                                                                cancer diagnostic and consultative services which include technical
      Number of Employees                     340                               laboratory services and professional interpretation. The company has its
      Industry                                Pharmaceuticals and Healthcare-   operations across the US. Clarient is headquartered at Aliso Viejo in
      Source:Primary / Secondary Research                                       California, the US.
      GlobalData




     Clarient, Inc. Pipeline Products

      Clarient, Inc. Key Pipeline Products by Equipment Type                    Clarient, Inc. Key Pipeline Products by Therapy Area

     Equipment Type                                          No of Products     Therapy Area                                           No of Products
     Immuno Chemistry                                               7           Breast cancer                                                 2
      Source: Primary / Secondary Research                                      Colorectal cancer                                              1
      GlobalData
                                                                                Head and neck cancer                                           1
                                                                                Leukemia                                                       1
                                                                                Lung cancer                                                    1
                                                                                Ovarian cancer                                                 1
                                                                                Source: Primary / Secondary Research
                                                                                GlobalData




      Clarient, Inc. Key Pipeline Products by Development Stage

     Developmental Stage                                                                                         No of Products
     Clinicals                                                                                                          1
     Pre-Clinicals                                                                                                     -
     Early development                                                                                                 2
      Source: Primary / Secondary Research
      GlobalData
      Note : (-) indicates 'Not Available'



      Clarient, Inc. Key Pipeline Products by Trial Phase

     Trial Phase                                                                                                 No of Products
     Phase IV                                                                                                          -
     Phase III                                                                                                         -
     Phase II                                                                                                          -
     Phase I                                                                                                           -
      Source: Primary / Secondary Research
      GlobalData
      Note : (-) indicates 'Not Available'




Clarient, Inc. (CLRT) - Product Pipeline Analysis                                                                                   Reference Code: GDMEPH4068PD

Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
     Table of Contents
     Table of Contents................................................................................................................................................................................................................................................................... 2
     List of Tables .......................................................................................................................................................................................................................................................................... 3
     List of Figures......................................................................................................................................................................................................................................................................... 3
     Clarient, Inc. - Business Description ...................................................................................................................................................................................................................................... 4
     Key Facts ............................................................................................................................................................................................................................................................................... 5
     Clarient, Inc. - Major Products and Services.......................................................................................................................................................................................................................... 6
           Clarient, Inc. Pipeline Products by Equipment Type ....................................................................................................................................................................................................... 7
           Clarient, Inc. Pipeline Products by Development Stage .................................................................................................................................................................................................. 9
           Clarient, Inc. Pipeline Products by Therapy Area .......................................................................................................................................................................................................... 11
           Clarient, Inc. Pipeline Products by Milestone Summary ................................................................................................................................................................................................ 13
           Head And Neck Cancer Assay ...................................................................................................................................................................................................................................... 15
                 Product Status......................................................................................................................................................................................................................................................... 15
                 Product Description ................................................................................................................................................................................................................................................. 15
           Insight Dx Colon Cancer................................................................................................................................................................................................................................................ 15
                 Product Status......................................................................................................................................................................................................................................................... 15
                 Product Description ................................................................................................................................................................................................................................................. 15
           Insight Dx Leukemia marker .......................................................................................................................................................................................................................................... 15
                 Product Status......................................................................................................................................................................................................................................................... 15
                 Product Description ................................................................................................................................................................................................................................................. 16
           Mammostrat Basal......................................................................................................................................................................................................................................................... 16
                 Product Status......................................................................................................................................................................................................................................................... 16
                 Product Description ................................................................................................................................................................................................................................................. 16
                 Product Milestone ................................................................................................................................................................................................................................................... 16
           Mammostrat erbB2 Assay ............................................................................................................................................................................................................................................. 17
                 Product Status......................................................................................................................................................................................................................................................... 17
                 Product Description ................................................................................................................................................................................................................................................. 17
                 Product Milestone ................................................................................................................................................................................................................................................... 17
           Ovotax ........................................................................................................................................................................................................................................................................... 18
                 Product Status.....................................................................................................................................................................................................
								
To top